Novel substituted piperidines

Use of a compound of the general formula (I′):

• 68
• wherein
• m is 1, 2 or 3,
• q is 0, 1 or 2,
• X is —CH2—(CH2)n—, —(CH2)n—CH═CH—(CH2)p—, —CH2—(CH2)n—O—(CH2)p—, —CH2—(CH2)n—C(═O)—(CH2)p—, —CH2—(CH2)n—S—(CH2)p—, —CH2—(CH2)n—S(═O)—(CH2)p— or —CH2—(CH2)n—S(═O)2—(CH2)p—,
• n and p are independently 0, 1, 2, 3 or 4,
• R1 and R2 are independently hydrogen, methyl or trifluoromethyl,
• Y is
• (a) aryl or heteroaryl, which may optionally be substituted with one or more substituents selected from
• halogen, nitro, cyano, hydroxy, C1-7-alkanoyl, C1-6-alkylthio, C1-6-alkylsulfonyl, C1-6-alkyl, C1-6-alkoxy, C3-8-cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR3R4 and —O(C═O)NR3R4,
• wherein R3 and R4 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl, C1-7-alkanoyl or aryl, or R3 and R4 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated ring,
• or wherein two substituents in adjacent positions form a radical —O—(CH2)1-3—O—,
• aryl, aryl-C1-6-alkyl and aryl-C1-6-alkoxy, wherein the ring moieties optionally may be substituted with one or more substituents selected from
• halogen, nitro, cyano, hydroxy, C1-7-alkanoyl, C1-6-alkylthio, C1-6-alkylsulfonyl, C1-6-alkyl, C1-6-alkoxy, C3-8-cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR5R6 and —O(C═O)NR5R6,
• wherein R5 and R6 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl, C1-7-alkanoyl or aryl, or R5 and R6 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated ring,
• or wherein two substituents in adjacent positions form a radical —O—(CH2)1-3—O
• (b) C3-8-cycloalkyl or C5-8-cycloalkenyl, which may optionally be substituted with one or more substituents selected from
• C1-6-alkyl, C1-6-alkoxy, C1-6-alkylthio, cyano, trifluoromethyl, trifluoromethoxy and halogen,
• aryl and aryloxy, wherein the ring moieties optionally may be substituted with one or more substituents selected from
• halogen, nitro, cyano, hydroxy, C1-7-alkanoyl, C1-6-alkylthio, C1-6-alkylsulfonyl, C1-6-alkyl, C1-6-alkoxy, C3-8-cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR7R8 and —O(C═O)NR7R8,
• wherein R7 and R8 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl, C1-7-alkanoyl or aryl, or R7 and R8 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated ring,
• or wherein two substituents in adjacent positions form a radical —O—(CH2)1-3—O—
• (c) C1-6-alkyl, C2-6-alkenyl and C2-6-alkynyl, which may optionally be substituted with one or more substituents selected from
• halogen, nitro, cyano, hydroxy, C1-7-alkanoyl, C1-6-alkylthio, C1-6-alkylsulfonyl, C1-6-alkoxy, C3-8-cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR9R10 and —O(C═O)NR9R10,
• wherein R9 and R10 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl, C1-7-alkanoyl or aryl, or R9 and R10 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated ring,
• aryl, aryl-C1-6-alkyl and aryl-C1-6-alkoxy, wherein the ring moieties optionally may be substituted with one or more substituents selected from
• halogen, nitro, cyano, hydroxy, C1-7-alkanoyl, C1-6-alkylthio, C1-6-alkylsulfonyl, C1-6-alkyl, C1-6-alkoxy, C3-8-cycloalkyl, trifluoromethyl, trifluoromethoxy, —NR11R12 and —O(C═O)NR11R12,
• wherein R11 and R12 independently are hydrogen, C1-6-alkyl, C3-8-cycloalkyl, C1-7-alkanoyl or aryl, or R11 and R12 together with the nitrogen atom to which they are attached form a 4 to 7 membered, saturated or unsaturated ring,
• or wherein two substituents in adjacent positions form a radical —O—(CH2)1-3—O—
• as well as any diastereomer or enantiomer or tautomeric form thereof including mixtures of these or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of disorders and diseases related to the histamine H3 receptor.